Netcapital (NCPL) Competitors $1.74 -0.06 (-3.33%) Closing price 03:59 PM EasternExtended Trading$1.76 +0.02 (+1.15%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock NCPL vs. NRBO, ANY, MCVT, GRYP, MIGI, GREE, AIHS, SLNH, LMFA, and CARVShould you be buying Netcapital stock or one of its competitors? The main competitors of Netcapital include NeuroBo Pharmaceuticals (NRBO), Sphere 3D (ANY), Mill City Ventures III (MCVT), Gryphon Digital Mining (GRYP), Mawson Infrastructure Group (MIGI), Greenidge Generation (GREE), Senmiao Technology (AIHS), Soluna (SLNH), LM Funding America (LMFA), and Carver Bancorp (CARV). These companies are all part of the "banking" industry. Netcapital vs. NeuroBo Pharmaceuticals Sphere 3D Mill City Ventures III Gryphon Digital Mining Mawson Infrastructure Group Greenidge Generation Senmiao Technology Soluna LM Funding America Carver Bancorp Netcapital (NASDAQ:NCPL) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap business services companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings. Which has more volatility and risk, NCPL or NRBO? Netcapital has a beta of -0.48, meaning that its stock price is 148% less volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Do analysts rate NCPL or NRBO? NeuroBo Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 532.91%. Given NeuroBo Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NeuroBo Pharmaceuticals is more favorable than Netcapital.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Netcapital 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NeuroBo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in NCPL or NRBO? 30.7% of Netcapital shares are held by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. 6.8% of Netcapital shares are held by insiders. Comparatively, 1.1% of NeuroBo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor NCPL or NRBO? In the previous week, Netcapital had 6 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 7 mentions for Netcapital and 1 mentions for NeuroBo Pharmaceuticals. Netcapital's average media sentiment score of 0.44 beat NeuroBo Pharmaceuticals' score of 0.00 indicating that Netcapital is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Netcapital 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroBo Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is NCPL or NRBO more profitable? NeuroBo Pharmaceuticals has a net margin of 0.00% compared to Netcapital's net margin of -562.71%. Netcapital's return on equity of -25.03% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Netcapital-562.71% -25.03% -22.67% NeuroBo Pharmaceuticals N/A -189.12%-122.31% Which has higher earnings and valuation, NCPL or NRBO? Netcapital has higher revenue and earnings than NeuroBo Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNetcapital$812.61K4.69-$4.99M-$20.20-0.09NeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/A Does the MarketBeat Community believe in NCPL or NRBO? NeuroBo Pharmaceuticals received 27 more outperform votes than Netcapital when rated by MarketBeat users. CompanyUnderperformOutperformNetcapitalN/AN/ANeuroBo PharmaceuticalsOutperform Votes2775.00% Underperform Votes925.00% SummaryNetcapital beats NeuroBo Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Remove Ads Get Netcapital News Delivered to You Automatically Sign up to receive the latest news and ratings for NCPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCPL vs. The Competition Export to ExcelMetricNetcapitalNondepository credit institutions IndustryBusiness SectorNASDAQ ExchangeMarket Cap$3.81M$7.60B$7.56B$8.32BDividend YieldN/A4.21%2.52%4.02%P/E Ratio-0.0516.7830.9019.25Price / Sales4.6910.22150.3894.09Price / CashN/A42.1531.5134.64Price / Book0.022.415.024.46Net Income-$4.99M$524.31M$194.85M$247.07M7 Day Performance-5.95%23.87%1.71%3.05%1 Month Performance-19.07%12.91%-2.71%-2.85%1 Year Performance-80.33%19.59%6.80%4.63% Netcapital Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCPLNetcapital0.251 of 5 stars$1.74-3.3%N/A-80.0%$3.81M$812,612.00-0.05N/ANRBONeuroBo Pharmaceuticals1.1348 of 5 stars$1.48-1.7%$10.00+575.7%-65.2%$12.75MN/A0.0010Upcoming EarningsNews CoverageGap UpANYSphere 3D1.9217 of 5 stars$0.49+0.2%$3.00+507.3%-65.6%$12.57M$21.66M-0.6220Analyst ForecastNews CoverageMCVTMill City Ventures III1.4735 of 5 stars$1.85-3.3%N/A-30.3%$11.81M$3.57M-26.422Upcoming EarningsNews CoverageGRYPGryphon Digital Mining1.4569 of 5 stars$0.22+4.3%N/A-87.0%$11.19M$7.69M0.00200Upcoming EarningsGap UpMIGIMawson Infrastructure Group1.943 of 5 stars$0.57+9.0%$2.00+250.9%-57.7%$10.66M$58.22M-0.1840Gap DownGREEGreenidge Generation2.7915 of 5 stars$0.89+9.1%$4.00+350.2%-73.4%$9.91M$64.38M0.00680AIHSSenmiao Technology0.0272 of 5 stars$0.88+2.3%N/A-12.2%$9.24M$5.88M-2.74150Positive NewsSLNHSoluna0.417 of 5 stars$1.07+10.3%N/A-65.3%$8.96M$39.87M-0.0760News CoverageLMFALM Funding America1.1372 of 5 stars$1.48+10.4%N/A-41.0%$7.60M$16.51M-0.308News CoveragePositive NewsGap UpCARVCarver Bancorp0.2386 of 5 stars$1.31-5.1%N/A-18.0%$6.69M$24.59M-0.68110Analyst ForecastNews Coverage Remove Ads Related Companies and Tools Related Companies NeuroBo Pharmaceuticals Competitors Sphere 3D Competitors Mill City Ventures III Competitors Gryphon Digital Mining Competitors Mawson Infrastructure Group Competitors Greenidge Generation Competitors Senmiao Technology Competitors Soluna Competitors LM Funding America Competitors Carver Bancorp Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NCPL) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Netcapital Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Netcapital With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NCPL Stock Free NCPL Stock Alerts